Heart Failure: Difference between revisions

Jump to navigation Jump to search
Line 216: Line 216:
== Management ==
== Management ==
The management of HF involves both pharmacological and non-pharmacological treatment. The emphasis is on the reduction in mortality and morbidity, prevention of the progression of HF, and the treatment of (non-)cardiovascular co-morbidities. Myocardial infarction (MI) is the most important cause of HF. Management of coronary disease is crucial in these patients, as revascularization of the myocardium will increase exercise capacity and survival.  
The management of HF involves both pharmacological and non-pharmacological treatment. The emphasis is on the reduction in mortality and morbidity, prevention of the progression of HF, and the treatment of (non-)cardiovascular co-morbidities. Myocardial infarction (MI) is the most important cause of HF. Management of coronary disease is crucial in these patients, as revascularization of the myocardium will increase exercise capacity and survival.  
Research shows that good adherence to medication is associated with a decrease in risk of death. (5) Nevertheless, the percentage of HF patients adhering to prescribed pharmacological and non-pharmacological treatment is as low as 20-60 % according to the literature (3-4).  
Research shows that good adherence to medication is associated with a decrease in risk of death. <cite>Granger</cite> Nevertheless, the percentage of HF patients adhering to prescribed pharmacological and non-pharmacological treatment is as low as 20-60 % according to the literature <cite>Evangelista</cite> <cite>VanDerWal</cite>.  
Treatment of diastolic- and systolic HF does not differ (vd wall). Non-pharmalogical treatment can be applied in every patient.
Treatment of diastolic- and systolic HF does not differ (vd wall). Non-pharmalogical treatment can be applied in every patient.
==== Non-pharmacological treatment ====
==== Non-pharmacological treatment ====
401

edits

Navigation menu